Evidence map›Paper›PMID 41836296›Full record

ArticleFrontiers in cell and developmental biology2026

FAM-related prognostic molecular subtype screening identified epithelial-derived

Hui Yu, Qingqiang Lei, Wenyong Yang, Min Cao, Miaoyu Zhang, Taisong Wang, Junhao Dong, Xuerui Chen, Xu Su, Yi Huang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hui Yu *Department of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Qingqiang Lei *Center of Bone Metabolism and Repair, Department of Wound Repair and Rehabilitation Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, Trauma Center, Research Institute of Surgery, Daping Hospital, Army Medical University, Chongqing, China.
Wenyong Yang *Department of Neurosurgery, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Min Cao *Department of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Miaoyu ZhangDepartment of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Taisong WangDepartment of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Junhao DongDepartment of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Xuerui ChenMedical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Xu SuMedical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Yi HuangDepartment of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
He XuDepartment of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Hui ZhuoDepartment of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.
Liangbin LinMedical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fatty acid metabolism (FAM) is essential for cancer cell proliferation and progression, contributing to membrane synthesis, energy storage, and signaling molecule production. However, effective therapeutic strategies targeting FAM are yet to be established in clinical practice. This study aimed to develop a novel FAM-related prognostic signature for bladder cancer (BLCA) and investigate its biological and clinical significance. Methods: We analyzed 359 BLCA samples and constructed a four-gene FAM-RiskScore (FAMR) signature based on FAM-related genes. Unsupervised clustering was performed to classify BLCA into molecular subtypes. The FAMR model was validated using internal and external cohorts. Functional enrichment, immune infiltration, and single-cell RNA sequencing analyses were conducted to explore underlying biological mechanisms. In vitro experiments, including proliferation and migration assays, were performed in T24 and 5637 bladder cancer cells following MAOA knockdown. Results: BLCA samples were classified into two subtypes (C1 and C2), with C1 showing better overall survival, enhanced steroid metabolism, downregulated chemokine signaling, and lower immune scores. The FAMR signature comprising PATZ1, TTC6, AEBP1, and MAOA was established. High FAMR scores-associated with low PATZ1, TTC6, MAOA, and high AEBP1 expression-predicted poor prognosis. FAMR positively correlated with pathways related to chemotaxis, inflammation, and cytoskeleton regulation, but negatively with fatty acid metabolism pathways. Higher FAMR scores were observed in females, patients aged >60, and advanced-stage tumors. Single-cell analysis revealed AEBP1 was mainly expressed in cancer-associated fibroblasts, while MAOA was enriched in cancer cells. Functional studies demonstrated that MAOA knockdown significantly enhanced proliferation and migration of bladder cancer cells in vitro. Discussion: We developed and validated a novel FAM-related risk signature that effectively predicts prognosis in BLCA. Our findings highlight MAOA as a potential tumor suppressor in bladder cancer, warranting further investigation as a therapeutic target. This FAMR model may facilitate risk stratification and inform personalized treatment strategies for bladder cancer patients.

Indexed as

bladder cancerfatty acid metabolismMAOAprognosis predictionsingle-cell RNA-seq

Identifiers

PMID41836296
PMCPMC12982390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.